The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 11, 2005
Filed:
Nov. 19, 2002
Carolyn J. Sympson, Ballwin, MO (US);
Rajeev Aurora, Glencoe, MO (US);
Stanton B. Dotson, Chesterfield, MO (US);
Ronald B. Frazier, Lake St. Louis, MO (US);
Cynthia L. Woods, St. Peters, MO (US);
Hamideh Zakeri, Chesterfield, MO (US);
Xianzhi Zhou, Chesterfield, MO (US);
Carolyn J. Sympson, Ballwin, MO (US);
Rajeev Aurora, Glencoe, MO (US);
Stanton B. Dotson, Chesterfield, MO (US);
Ronald B. Frazier, Lake St. Louis, MO (US);
Cynthia L. Woods, St. Peters, MO (US);
Hamideh Zakeri, Chesterfield, MO (US);
Xianzhi Zhou, Chesterfield, MO (US);
Pharmacia Corporation, St. Louis, MO (US);
Abstract
Methionine aminopeptidases catalyse the co-translational removal of amino terminal methionine residues from nascent polypeptide chains. A newly-discovered enzyme, designated methionine aminopeptidase type-3 (MetAP-3), has a substrate specificity which is similar to MetAP-1 and MetAP-2, although it is not inhibited by fumagillin, an irreversible inhibitor of MetAP-2. MetAP-3 also preferentially localizes to mitochondria, unlike MetAP-1 and MetAP-2, which accumulate in the cytoplasm. One embodiment of the present invention relates to human cDNAs encoding polypeptides comprising MetAP-3. Other embodiments of the invention relate to nucleic acid molecules derived from these cDNAs, including complements, homologues, and fragments thereof, and methods of using these nucleic acid molecules, to generate polypeptides and fragments thereof. Other embodiments of the invention relate to antibodies directed against polypeptides comprising MetAP-3, and methods to screen for compounds or compositions that preferentially or specifically effect the activity of polypeptides comprising MetAP-3.